Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.

Saved in:
Bibliographic Details
Title: Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Authors: Vera P; Nuclear Medicine Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France. Electronic address: pierre.vera@chb.unicancer.fr., Thureau S; Radiotherapy Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France., Le Tinier F; Radiotherapy Department, Centre Oscar Lambret, Lille, France., Chaumet-Riffaud P; Clinical Research Department, Hôpital National des 15-20, Paris, France., Hapdey S; Nuclear Medicine Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France., Kolesnikov-Gauthier H; Nuclear Medicine Department, Centre Oscar Lambret, Lille, France., Martin E; Radiotherapy Department, Centre Georges-François Leclerc, Dijon, France., Berriolo-Riedinger A; Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France., Pourel N; Unité Fonctionnelle Onco-Thoracique, Institut du Cancer, Avignon, France., Broglia JM; Nuclear Medicine Deparment, Institut Sainte-Catherine, Avignon, France., Boissellier P; Radiotherapy Department, Institut du Cancer de Montpellier, Montpellier, France., Guillemard S; Nuclear Medicine Department, Institut du Cancer de Montpellier, Montpellier, France., Salem N; Radiotherapy Department, Institut Paoli-Calmettes, Marseille, France., Brenot-Rossi I; Nuclear Medicine Department, Institut Paoli-Calmettes, Marseille, France., Le Péchoux C; Radiation Oncology Department, Gustave Roussy, Villejuif, France., Berthold C; Radiation Oncology Department, Gustave Roussy, Villejuif, France., Giroux-Leprieur E; University Paris-Saclay, Department of Respiratory Diseases and Thoracic Oncology, Assistance Publique-Hôpitaux de Paris, Ambroise Paré Hospital, Boulogne-Billancourt, France., Moreau D; Oncology Radiotherapy Department, Paris Cité University, European Hospital Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France., Guillerm S; Department of Radiation Therapy, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France., Benali K; Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris Nord, Paris, France., Tessonnier L; Nuclear Medicine Department, Centre Intercommunal Sainte-Musse de Toulon-La Seyne-sur-mer, Toulon, France., Audigier-Valette C; Pneumology Department, Centre Intercommunal Sainte-Musse de Toulon-La Seyne-sur-mer, Toulon, France., Lerouge D; Radiotherapy Department, Centre Francois Baclesse, Caen, France., Quak E; Nuclear Medicine Department, Centre Francois Baclesse, Caen, France., Massabeau C; Radiotherapy Department, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Courbon F; Nuclear Medicine Department, Institut Claudius Regaud - Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Moisson P; Radiotherapy Department, Hopital René Huguenin - Institut Curie, Saint-Cloud, France., Larrouy A; Radiotherapy Department, Centre de Cancerologie Paris Nord, Sarcelles, France., Modzelewski R; Nuclear Medicine Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France., Gouel P; Nuclear Medicine Department and QuantIF LITIS (EA4108), Centre Henri Becquerel, Rouen, France., Ghazzar N; Nuclear Medicine Department, Paris Cité University, European Hospital Georges-Pompidou - Assistance Publique-Hôpitaux de Paris Centre, Paris, France., Langlais A; Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris, France., Amour E; Clinical Research Unit, Intergroupe Francophone de Cancérologie Thoracique, Paris, France., Zalcman G; Université Paris Cité, Thoracic Oncology Department, Centre d'Investigation Clinique Institut National de la Santé et de la Recherche Médicale 1425, Hôpital Bichat-Claude Bernard, Institut du Cancer - Assistance Publique-Hôpitaux de Paris Nord, Paris, France., Giraud P; Oncology Radiotherapy Department, Paris Cité University, European Hospital Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
Source: The Lancet. Oncology [Lancet Oncol] 2024 Sep; Vol. 25 (9), pp. 1176-1187. Date of Electronic Publication: 2024 Aug 09.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(24)00320-6